Author name: Leonardo Arias

Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the small- to mid-cap pharmas best prepared to bolster their pipelines with a buyout.

The medtech firm is using Nvidia’s technology in its Monarch robotic platform for urology.

The healthcare giant beat Wall Street expectations in the third quarter and raised its 2025 earnings guidance, albeit modestly.

CEO Bob White and Chief Strategy Officer Gabriela Kaynor discussed the medtech company’s quality and technology priorities after a year of change.

Measuring financial returns from AI can be challenging, experts said at the HLTH conference last week. But other metrics, like provider and patient satisfaction, are important too — and also impact providers’ bottom lines.

Patients treated with Symplicity Spyral had significantly lower blood pressure than people who received a sham treatment after three years.

Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal has not yet been reached.

Cuando se habla de medicina estética, muchas veces pensamos en retoques superficiales. Pero la realidad es que hoy estamos en un momento de transformación profunda. Y si bien profesionales como Diego Casas, especialista en rinoplastia aparecen en el debate público por sus interv …

Phase III data for dapirolizumab pegol presented at the 2025 conference of the American College of Rheumatology showed quality-of-life benefits in systemic lupus erythematosus that could see Biogen go head-to-head with GSK and AstraZeneca in a blockbuster space.

BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending competition for achondroplasia therapy Voxzogo and the divestment of the gene therapy Roctavian.